Investing in health is increasingly being viewed as an economic and development priority, rather than a simple healthcare expense. Dr. Olfat Berro, the Area Head for the Middle East at Roche, argues that strong economies rely on healthy, productive populations. Aging demographics and rising chronic diseases put pressure on entire societies, not just healthcare systems. Amidst inflation and geopolitical uncertainty, governments face difficult choices about where to allocate capital. When disease limits independence, its macroeconomic impact is profound, as global productivity losses due to poor health can reduce GDP by up to 15 percent each year.
The Economic Toll of Chronic Disease
Non-communicable diseases are already creating a massive burden across the Middle East, accounting for approximately 74 percent of deaths in the region. Cardiovascular disease is responsible for an estimated 1.4 million deaths annually, while diabetes contributes to about 796,000 deaths. Globally, chronic diseases are projected to cost the world economy more than US$47 trillion by 2030. This burden is particularly disruptive for a region with an economically active population. Diabetes often leads to severe complications like Diabetic Macular Edema, which strikes roughly 50 percent of patients between 40 and 60 years old. When the disease hits during this peak period of economic activity, it disrupts workforce productivity, household stability, and corporate leadership.
The financial scale of this issue is undeniable. In Saudi Arabia alone, the annual economic burden of diabetes-related visual impairment stands at a staggering SAR 150.3 billion, or US$40.1 billion. This figure reflects both direct medication costs and massive productivity losses. Furthermore, these diseases create a severe “caregiver double-drain.” Because treatments often temporarily blur vision, an active caregiver must take time off work to drive the patient to frequent, regular clinic appointments. This multiplies lost working hours for both individuals and disproportionately affects female workforce participation. The burden of non-communicable diseases is therefore fundamentally an economic challenge, reinforcing the importance of acting earlier to keep people independent and contributing to society for longer.
Read Also: Venus Nova Provides Non-Invasive Post-Weight Loss Contouring
Why Health Spending Drives Development
Partnerships and policy changes are necessary to integrate health into the region’s economic agenda. This approach ensures that health systems support broader development goals.
Strategies for Economic Return
Effective strategies begin with prevention and awareness. Governments must invest in systematic screening and early diagnosis. For diseases that progress silently, waiting for symptoms often means irreversible damage has already occurred. Acting early provides a strong economic return. Across the GCC, every US$1 invested in addressing non-communicable diseases could generate approximately US$4.90 in return. This investment would also help avert around 290,000 premature deaths.
Innovation is also vital for success. Deploying decentralized, AI-driven screening systems within Primary Healthcare Centers can expand screening capacity. These systems help identify at-risk patients earlier. They also make better use of limited specialist capacity. Technology only delivers its full value when embedded within connected care pathways. These pathways must link primary care, diagnostics, specialists, and long-term support.
Read Also: Gulf Nations Compete to Attract Medical Tourists
Empirical data gathered outside clinical trials carries equal significance. Such information reveals how illnesses manifest within Middle Eastern populations. It identifies points where individuals drop out of care pathways and evaluates whether treatments achieve intended results in everyday medical environments. Generating locally relevant evidence strengthens policymaking, enabling smarter distribution of resources and designing care frameworks tailored to regional needs. Additionally, healthcare systems must minimize logistical obstacles for patients. Frequent treatments often result in poor adherence and strain clinical workflows. Transitioning to longer-lasting therapies for diabetic eye conditions becomes essential. Integrating sustained-release treatments and adopting value-based payment structures can improve outcomes while protecting hospital capacity and promoting long-term fiscal stability.
Policy and Partnerships
Healthcare reform cannot be shouldered by the medical field in isolation. It demands collaborative engagement among public institutions, financial bodies, corporate entities, educational organizations, and private enterprises. Strategic alliances form the foundation of meaningful progress. Industry’s function extends past delivering novel solutions—it includes partnering with health systems to tackle operational gaps. The objective centers on ensuring enduring accessibility. This necessitates evolving past conventional fee-for-service arrangements toward genuine Public-Private Partnerships.
Through jointly crafted risk-sharing contracts and outcome-linked reimbursement schemes, both sectors can align economic incentives with measurable health improvements such as preserved vision or decreased hospital readmissions. Doing so reduces exposure for public insurers. Across the Middle East, enthusiasm for healthcare modernization is accelerating. Now lies the chance to capitalize on this energy—supporting robust systems that enhance patient experiences while producing clear economic benefits for the region.
